Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

被引：21

作者：

Qiao, Yu ^{[1
,2
]}

Yang, Jihong ^{[1
,3
]}

Liu, Lili ^{[1
,3
]}

Zeng, Yixin ^{[1
,2
]}

Ma, Jie ^{[4
]}

Jia, Jing ^{[1
]}

Zhang, Li ^{[5
]}

Li, Xiaoguang ^{[6
]}

Wu, Peihong ^{[7
]}

Wang, Wenchao ^{[8
]}

Liu, Dongge ^{[9
]}

Chen, Huan ^{[1
,3
]}

Zhao, Yunbo ^{[1
,2
]}

Xi, Huan ^{[1
]}

Wang, Yao ^{[1
]}

机构：

[1] Beijing Hosp, Natl Ctr Gerontol, Dept Geriatr, Beijing 100730, Peoples R China

[2] Beijing Hosp, Natl Ctr Gerontol, Dept Oncol, Beijing 100730, Peoples R China

[3] Beijing Hosp, Natl Ctr Gerontol, Dept Nephrol, Beijing 100730, Peoples R China

[4] Beijing Hosp, Natl Ctr Gerontol, Biol Treatment Ctr, Beijing 100730, Peoples R China

[5] Zhongshan Univ, Tumor Hosp, Dept Oncol, Guangzhou 510089, Guangdong, Peoples R China

[6] Beijing Hosp, Natl Ctr Gerontol, Minimally Invas Tumor Therapies Ctr, Beijing 100730, Peoples R China

[7] Zhongshan Univ, Tumor Hosp, Ctr Med Image Guided Minimally Invas Therapy, Guangzhou 510089, Guangdong, Peoples R China

[8] Beijing Hosp, Natl Ctr Gerontol, Dept Imaging, Beijing 100730, Peoples R China

[9] Beijing Hosp, Natl Ctr Gerontol, Dept Pathol, Beijing 100730, Peoples R China

来源：

BMC CANCER | 2018年 / 18卷

关键词：

Primary hepatic angiosarcoma; Pazopanib; PD-1; inhibitor; RAK cell; IMMUNOTHERAPY; CARCINOMA; ABLATION; FEATURES; OUTCOMES; LIVER;

D O I：

10.1186/s12885-018-3996-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. Case presentation: A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor. Conclusion: Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.

引用

页数：5

共 50 条

[21] PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report [J].

Du, YunYi ;

Zhang, XiaoLing ;

Zhang, Ying ;

Li, WeiLing ;

Hu, WenQing ;

Zong, Liang ;

Zhao, Jun .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)

[22] Case report: Significant response to PD-L1 inhibitor after resistance to PD-1 inhibitor in an advanced alpha-fetoprotein-positive gastric cancer [J].

Wang, Liyu ;

Feng, Ying ;

Huang, Anquan ;

Shi, Jianming ;

Zhang, Qinying ;

Zhu, Fan ;

Lv, Bin ;

Guo, Fen ;

Zou, Tianming ;

Zhang, Luyao .

FRONTIERS IN ONCOLOGY, 2022, 12

[23] Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report [J].

Gelsomino, Francesco ;

Di Federico, Alessandro ;

Filippini, Daria M. ;

Dall'Olio, Filippo G. ;

Lamberti, Giuseppe ;

Sperandi, Francesca ;

Balacchi, Caterina ;

Brocchi, Stefano ;

Ardizzoni, Andrea .

CLINICAL LUNG CANCER, 2020, 21 (02) :E45-E48

[24] PD-1 Inhibitor Plus Chemotherapy as 2nd/Subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC [J].

Ren, S. ;

Liu, Y. ;

Zhou, F. ;

Jiang, T. ;

Su, C. ;

Chen, X. ;

Zhou, C. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S135-S136

[25] Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review [J].

Zheng, Weicheng ;

Xue, Qingfeng ;

Sha, Xueping ;

Wang, Yao ;

Wang, Yuan ;

Liu, Juan ;

Zhang, Yaping ;

Shi, Wenyu .

CANCER BIOLOGY & THERAPY, 2021, 22 (10-12) :537-543

[26] Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients [J].

Wei, Jia ;

Lu, Xiaofeng ;

Liu, Qin ;

Li, Lin ;

Liu, Song ;

Liu, Fangcen ;

Fu, Yao ;

Fan, Xiangshan ;

Yang, Yang ;

Qi, Chuang ;

Yu, Yangyang ;

Guan, Wenxian ;

Liu, Baorui .

FRONTIERS IN ONCOLOGY, 2021, 10

[27] Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer [J].

Zhang, Ting ;

Zhu, Chengpei ;

Zhang, Nan ;

Zhang, Longhao ;

Wang, Shanshan ;

Xun, Ziyu ;

Xu, Yiyao ;

Yang, Xiaobo ;

Lu, Xin ;

Zhao, Haitao .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 129

[28] PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy as First-line Treatment for Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis [J].

Lu, Yao ;

Xu, Mengli ;

Guan, Lulu ;

Yang, Yalan ;

Chen, Yu ;

Yang, Yuanyuan ;

Wang, Feng .

JOURNAL OF IMMUNOTHERAPY, 2022, 45 (05) :243-253

[29] Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report [J].

Zhang, Ze ;

Zhang, Wenwen ;

Wang, Hongguang ;

Hu, Bingyang ;

Wang, Zhanbo ;

Lu, Shichun .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[30] Efficacy and safety of PD-1 inhibitor plus chemotherapy in advanced nasopharyngeal carcinoma: A meta-analysis [J].

Yan, Xin ;

Chen, Suhua ;

Dai, Guoping ;

Liu, Yingxin .

TUMORI JOURNAL, 2025, 111 (01) :88-99

← 1 2 3 4 5 →